Overview

Safety and Tolerability Study of MCI-196

Status:
Terminated

Trial end date:
2014-12-01

Target enrollment:

Participant gender:

Summary

The objective of this study is to assess the safety and tolerability of colestilan (MCI-196) in paediatric subjects (aged 2 years to <18 years) with CKD stages 3b to 5, diagnosed with hyperphosphataemia, who are not on dialysis.

Phase:

Phase 3

Details

Lead Sponsor:

Mitsubishi Tanabe Pharma Corporation